Sickle Cell Disease is a life‑threatening genetic condition that has been left behind by a system that funds profit over people
+
WHAT IS SICKLE CELL
Sickle Cell Disease (SCD) is a genetic blood disorder that predominately affects black and brown communities. It transforms round, flexible red blood cells into stiff, crescent-shaped "sickles."
These malformed cells get stuck in tiny blood vessels, cutting off oxygen flow and triggering a domino effect of intense pain, organ damage, chronic fatigue, and stroke.
+
INSIDE THE BODY
WHEN BLOOD CELLS SICKLE, THEY BLOCK OXYGEN, TRIGGER CRISIS-LEVEL PAIN, AND QUIETLY STRAIN ORGANS AND IMMUNITY ACROSS THE WHOLE BODY
FACT 1
THE VASCULAR TRAFFIC JAM:
Sticky, sickle-shaped cells clog the bloodstream, causing sudden, excruciating "pain crises."
FACT 2
THE OXYGEN DEFICIT:
Short-lived red cells lead to chronic anemia, leaving the body in a constant state of exhaustion.
FACT 3
THE SILENT ORGAN STRAIN:
Restricted blood flow causes gradual, invisible damage to the heart, lungs, and kidneys.
FACT 4
THE IMMUNE VULNERABILITY:
A compromised spleen leaves the body's defences down, turning minor infections into major risks.
+
EQUITY CONTRAST
Sickle Cell Disease and Cystic Fibrosis: A contrast in care
SCD AFFECTS APPROXIMATELY 3 TIMES AS MANY PEOPLE IN THE U.S. AS CF.
CF RECEIVES ROUGHLY 3.4 TIMES MORE NIH FUNDING AND VASTLY MORE PRIVATE SUPPORT THAN SCD.
CF PRIMARILY AFFECTS WHITE INDIVIDUALS, WHILE SCD DISPROPORTIONATELY AFFECTS BLACK AMERICANS
+
Federal (NIH) Investment Gap
CYSTIC FIBROSIS:
~$2,807 per person.
SICKLE CELL DISEASE:
~$812 per person.
THE "3.5 TIMES" RULE:
For every $1 spent on an SCD patient, the government spends $3.50 on a CF patient.
+
The Philanthropic "Wealth Gap"
75 TIMES DIFFERENCE:
National foundation spending for CF is estimated to be 75 to 100 times higher than for SCD.
DONOR NETWORKS:
One analysis showed foundation spending at $7,600 per person for CF, compared to a mere $102 per person for SCD.
GLOBAL TRENDS:
In the UK, over 73% of research grants were awarded to CF, while SCD received less than 20%.
+
The Innovation Gap
DRUG APPROVALS:
Between 2008 and 2018, the FDA approved 4 new drugs for CF but only 1 for SCD.
THE COST OF "CURES":
While new gene therapies are groundbreaking, their $2M–$3M price tags create a new barrier.
THE ACCESSIBILITY CRISIS:
There is a growing concern that even when "cures" are found, they remain out of reach for the low-income communities most affected by SCD.